Central nervous system origin vertigo

Summary

Central nervous system origin vertigo (MONDO:0002317) is a disease with 6 GWAS associations across 6 studies. A subtype of brain disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	central nervous system origin vertigo
Mondo ID	MONDO:0002317
DOID	DOID:2479
SNOMED CT	38403006
UMLS	C0155503
MedGen	56365
Is cancer (heuristic)	no

Also known as: vertigo of central origin

Data availability: 6 GWAS associations (6 studies).

Disease family

This is a subtype of brain disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › central nervous system origin vertigo

Related subtypes (70): leukoencephalopathy, megalencephalic, encephalopathy, acute, infection-induced, diabetic encephalopathy, complex cortical dysplasia with other brain malformations, hydrocephalus, brain compression, cerebral sarcoidosis, hepatic encephalopathy, visual pathway disorder, cerebellar disorder, cerebritis, olfactory nerve disorder, thalamic disorder, pituitary gland disorder, disorder of optic chiasm, basal ganglia disorder, epilepsy, mental disorder, central nervous system cyst, migraine disorder, multiple sclerosis, prion disease, carbon monoxide-induced delayed encephalopathy, cerebral malaria, akinetic mutism, bulbar polio, Reye syndrome, brain edema, encephalomalacia, intracranial hypertension, intracranial hypotension, Wernicke encephalopathy, encephalopathy, recurrent, of childhood, XK aprosencephaly, progressive bulbar palsy, cerebrovascular disorder, glycine encephalopathy, autosomal recessive frontotemporal pachygyria, occipital pachygyria and polymicrogyria, insomnia, narcolepsy-cataplexy syndrome, megalencephaly, meningoencephalocele, cerebral cortical dysplasia, encephaloclastic disorder, bilirubin encephalopathy, autoimmune encephalopathy with parasomnia and obstructive sleep apnea, narcolepsy without cataplexy, hypothalamic hamartomas with gelastic seizures, encephalitis, cerebral lipidosis with dementia, brain neoplasm, colpocephaly, corpus callosum agenesis of blepharophimosis robin type, corpus callosum dysgenesis X-linked recessive, corpus callosum dysgenesis cleft spasm, corpus callosum dysgenesis hypopituitarism, cerebral degeneration, acute bilirubin encephalopathy, chronic bilirubin encephalopathy, atelencephaly, aprosencephaly, brain injury, traumatic encephalopathy, cluster headache syndrome, cerebral cortex disorder, midbrain disorder, encephalopathy due to mitochondrial and peroxisomal fission defect, brain malformations with or without urinary tract defects, encephalopathy, acute transient

Genetics & variants

GWAS landscape

6 GWAS associations across 6 studies. Top hits map to 2 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs10862089	1e-30	OTOGL	G	0.24
rs426564	2e-29	ZNF91	G	0.14
chr19:23486668	5e-24		A	0.15
rs2980097	1e-12	TMEM128 - LYAR	C	0.09

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475907	Verma A	2024	13,472	421,612	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477814	Verma A	2024	2,768	115,422	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480112	Verma A	2024	2,768	115,422	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475906	Verma A	2024	1,863	55,550	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436046	Zhou W	2018	380	402,827	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90043831	Jiang L	2021	284	456,064	A generalized linear mixed model association tool for biobank-scale data.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	1
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	3

MAF distribution

Bucket	Variants
common (>=0.05)	4
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intergenic_variant	2
missense_variant	1
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs10862089	12	80305695	G>T	0.081	missense_variant	OTOGL	1e-30	Tier 1: coding
rs426564	19	23314211	G>A,C	0.308	intergenic_variant	ZNF91	2e-29	Tier 4: intronic/intergenic
chr19:23486668				0.212			5e-24	Tier 4: intronic/intergenic
rs2980097	4	4251914	C>A,G	0.395	intergenic_variant	TMEM128 - LYAR	1e-12	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.